Previous 10 | Next 10 |
NESS ZIONA, Israel, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will p...
- Sol-Gel to receive $21 million over 24 months in exchange for the transfer of its rights to two marketed generic drugs and eight unapproved generic programs - Sol-Gel to retain two generic programs encompassing four high-value generic drug candidates ...
NESS ZIONA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will ...
NESS ZIONA, Israel, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will ...
Sol-Gel Technologies (NASDAQ:SLGL): Q2 GAAP EPS of $0.35 beats by $0.56. Revenue of $0.9M (-20.4% Y/Y) misses by $2M. Press Release For further details see: Sol-Gel Technologies EPS beats by $0.56, misses on revenue
Recently obtained FDA approval of TWYNEO ® triggers milestone payment from Galderma Exclusive license agreements with Galderma for U.S. commercialization of EPSOLAY ® and TWYNEO Sol-Gel adv ancing its early-stage pipeline in plaque psoriasis...
Bet_Noire/iStock via Getty Images The U.S. FDA has approved Sol-Gel Technologies' ([[SLGL]]) TWYNEO (tretinoin/benzoyl peroxide) cream, 0.1%/3%, for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older. TWYNEO, which is patent protected until 2038, was a...
TWYNEO ® , a once-daily cream treatment for acne vulgaris, is the first FDA-approved fixed-dose combination of tretinoin and benzoyl peroxide TWYNEO utilizes Sol-Gel’s proprietary microencapsulation technology and is patent protected until 2038 Un...
NESS ZIONA, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quart...
Sol-Gel Technologies (SLGL) and Galderma has signed two exclusive five-year license agreements for the commercialization of Epsolay and Twyneo in the United States. Under the pact, Galderma has an exclusive license to commercialize Sol-Gel's advanced investigational drug products using Sol-Ge...
News, Short Squeeze, Breakout and More Instantly...
Sol-Gel Technologies Ltd. Company Name:
SLGL Stock Symbol:
NASDAQ Market:
Sol-Gel Technologies Ltd. Website:
NESS ZIONA, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved...
NESS ZIONA, Israel, May 28, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved ...